13F COMBINATION REPORT
Crestline Management, LP
Quarter ended Q3 2025 · Filed November 14, 2025 · Accession 0001315863-25-000800
Total Value
$58.1M
Positions
3
Other Managers
0
Confidential Omitted
No
Holdings (3)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | DENALI THERAPEUTICS INC | DNLI | 3,410,732 | $49.5M | 85.26% |
| 2 | SANA BIOTECHNOLOGY INC | SANA | 1,820,937 | $6.5M | 11.13% |
| 3 | 8X8 INC NEW | 282914100 | 990,580 | $2.1M | 3.62% |